Glenmark Pharmaceuticals, USA (Glenmark) has received final approval by the United States Food & Drug Administration (USFDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), determined by the FDA to be bioequivalent1 to Pataday2 Once Daily Relief Ophthalmic Solution, 0.2% (OTC), of Alcon Laboratories, Inc. Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the U.S. by Glenmark Therapeutics, USA.
According to Nielsen syndicated data for the latest 52 weeks’ period ending February 22, 2025, the Pataday® Once Daily Relief Ophthalmic Solution, 0.2% (OTC) market3 achieved annual sales of approximately $50.7 million.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are pleased to continue to expand our OTC ophthalmic portfolio. The addition of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% highlights our commitment to meeting market needs and providing quality over-the-counter solutions for our customers.”
This flyer announces a Walk-In Drive for Apitoria Pharma Private Limited (a 100% subsidiary of…
WE ARE HIRING | IPQA: Officer/Executive 📍 Location: Shamirpet, Hyderabad 🏢 Granules Life Sciences 💼…
We’re Hiring: QA & QC Sampling (B.Sc. Chemistry Freshers) at Macleods Centre of Excellence 🧪…
We’re Hiring Exciting Career Opportunities for Freshers in a Core Chemical Industry ! Are you…
Walk-In For Apprentice Production Packing-Taloja Flamingo Pharmaceuticals Time and Venue 19th November - 20th November , 10.30…
Greetings of the day!! We are inviting freshers for Walk in Interview for Backend Non…